Medical trial finds ticagrelor–aspirin antiplatelet therapy more beneficial in persons with normal renal function
‘A silent killer’: COVID-19 shown to trigger inflammation in the brain
1 November 2022Urine bicarbonate test offers new, safe quantification of CFTR function in cystic fibrosis patients
1 November 2022Medical trial finds ticagrelor–aspirin antiplatelet therapy more beneficial in persons with normal renal function
An analysis of the CHANCE-2 trial has found that persons with normal renal function receive greater benefit from antiplatelet therapy with ticagrelor–aspirin versus clopidogrel–aspirin. The analysis is published in Annals of Internal Medicine.
